- Home
- EGY vs CGEM Comparison
EGY vs CGEM Comparison
Compare EGY & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CGEM
- Stock Information
- Founded
- EGY 1985
- CGEM 2016
- Country
- EGY United States
- CGEM United States
- Employees
- EGY N/A
- CGEM N/A
- Industry
- EGY Oil & Gas Production
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CGEM Health Care
- Exchange
- EGY Nasdaq
- CGEM Nasdaq
- Market Cap
- EGY 412.9M
- CGEM 437.2M
- IPO Year
- EGY N/A
- CGEM 2021
- Fundamental
- Price
- EGY $3.74
- CGEM $8.53
- Analyst Decision
- EGY
- CGEM Strong Buy
- Analyst Count
- EGY 0
- CGEM 7
- Target Price
- EGY N/A
- CGEM $26.00
- AVG Volume (30 Days)
- EGY 701.9K
- CGEM 793.3K
- Earning Date
- EGY 11-10-2025
- CGEM 11-06-2025
- Dividend Yield
- EGY 6.68%
- CGEM N/A
- EPS Growth
- EGY N/A
- CGEM N/A
- EPS
- EGY 0.27
- CGEM N/A
- Revenue
- EGY $389,951,000.00
- CGEM N/A
- Revenue This Year
- EGY N/A
- CGEM N/A
- Revenue Next Year
- EGY $23.20
- CGEM N/A
- P/E Ratio
- EGY $13.86
- CGEM N/A
- Revenue Growth
- EGY N/A
- CGEM N/A
- 52 Week Low
- EGY $3.00
- CGEM $5.68
- 52 Week High
- EGY $5.47
- CGEM $14.15
- Technical
- Relative Strength Index (RSI)
- EGY 44.23
- CGEM 58.64
- Support Level
- EGY $3.66
- CGEM $7.93
- Resistance Level
- EGY $3.95
- CGEM $9.10
- Average True Range (ATR)
- EGY 0.12
- CGEM 0.66
- MACD
- EGY -0.01
- CGEM 0.07
- Stochastic Oscillator
- EGY 25.00
- CGEM 77.20
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.